Bioceltix S.A.

Warsaw Stock Exchange BCX.WA

Bioceltix S.A. Operating Cash Flow for the year ending December 31, 2023: USD -3.74 M

Bioceltix S.A. Operating Cash Flow is USD -3.74 M for the year ending December 31, 2023, a -107.25% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Bioceltix S.A. Operating Cash Flow for the year ending December 31, 2022 was USD -1.80 M, a -80.53% change year over year.
  • Bioceltix S.A. Operating Cash Flow for the year ending December 31, 2021 was USD -999.54 K, a -146.92% change year over year.
  • Bioceltix S.A. Operating Cash Flow for the year ending December 31, 2020 was USD -404.80 K, a 7.86% change year over year.
  • Bioceltix S.A. Operating Cash Flow for the year ending December 31, 2019 was USD -439.35 K, a 7.88% change year over year.
Key data
Date Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid
Market news
SV Wall Street
Warsaw Stock Exchange: BCX.WA

Bioceltix S.A.

CEO Mr. Lukasz Bzdzion
IPO Date Nov. 8, 2021
Location Poland
Headquarters Building III
Employees 28
Sector Healthcare
Industries
Biotechnology Pet Food Pharmaceuticals
Description

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.

StockViz Staff

February 6, 2025

Any question? Send us an email